Modernland Realty Ltd
MDLN
$41.11
+4.23%
Medline is the largest provider of medical-surgical products and supply chain solutions in the US, offering over 190,000 branded products and 150,000 third-party items to major health systems. As a dominant player in the medical supplies industry, it leverages extensive scale with more than 30 manufacturing facilities and a fleet of 2,000 delivery trucks. The company went public in December 2025, and the current investor narrative centers on near-term operational challenges, including a distribution center fire and an FDA warning letter, which have created headwinds but may be mitigated by its scale and market position.…
MDLN
Modernland Realty Ltd
$41.11
Related headlines
Investment Opinion: Should I buy MDLN Today?
Rating: Buy. Medline's dominant market position, strong free cash flow, and attractive valuation relative to its history and analyst targets make it a compelling investment for those willing to tolerate near-term operational volatility. The consensus analyst rating is Buy with an average target price of $50.92, implying 29.1% upside.
Supporting Evidence: The company's revenue growth of 10.7% YoY outpaces many peers, and its forward PE of 23.7x is reasonable given expected EPS of $2.37. The trailing PE of 29.4x is near the low end of its historical range (24.4x-69.5x), suggesting limited downside from valuation compression. Free cash flow of $1.525 billion TTM provides a 4.5% yield relative to market cap, and the dividend yield of 1.5% adds income. The analyst high target of $62.00 implies 57% upside, reflecting potential for a strong recovery.
Risks & Conditions: The biggest risks are the operational disruptions from the fire and FDA issues, which could further depress margins and earnings. This Buy rating would be downgraded to Hold if revenue growth falls below 8% or if gross margin drops below 20%. It would be upgraded to Strong Buy if the company resolves the FDA warning letter and restores margins to 24%+ within two quarters. Overall, the stock appears undervalued relative to its historical multiples and analyst targets, but near-term headwinds warrant caution.
Sign up to view all
MDLN 12-Month Price Forecast
The AI assessment is bullish with medium confidence, driven by Medline's strong revenue growth, attractive valuation relative to its history, and significant analyst upside. The key risk is the near-term operational headwinds from the fire and FDA issues, which could delay margin recovery. However, the company's dominant market position, healthy free cash flow, and reasonable forward PE suggest that the current price offers a favorable entry point for long-term investors. The stance would be upgraded to high confidence if the company reports a quarter with improving margins, and downgraded to neutral if revenue growth decelerates below 8% or if the FDA issues escalate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Modernland Realty Ltd's 12-month outlook, with a consensus price target around $50.92 and implied upside of +23.9% versus the current price.
Average Target
$50.92
0 analysts
Implied Upside
+23.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $62
Analyst target range
The stock is covered by 26 analysts, with a consensus recommendation of 'Buy' (mean score 1.54 on a 1-5 scale, where 1 is Strong Buy). The average target price is $50.92, implying 29.1% upside from the current price of $39.44. The distribution shows 10 recent ratings with no downgrades, indicating strong bullish sentiment. The target range spans from $40.00 (low) to $62.00 (high). The high target assumes a recovery in operations and multiple expansion, while the low target reflects continued headwinds from the fire and FDA issues. The wide spread ($22) signals high uncertainty, but the consensus remains bullish. Recent ratings from Baird, Barclays, and others have maintained positive stances, reinforcing the favorable outlook.
Bulls vs Bears: MDLN Investment Factors
Medline presents a mixed picture: it is a dominant player in a stable industry with strong revenue growth and significant analyst upside, but it faces near-term operational challenges from a distribution center fire and FDA issues that have compressed margins and earnings. The bull case rests on the company's scale, free cash flow, and potential for earnings recovery, while the bear case focuses on declining profitability, decelerating growth, and operational headwinds. Currently, the bearish factors appear more immediate, but the long-term value proposition and analyst consensus suggest a potential turnaround. The single most important tension is whether the operational issues are temporary and manageable, allowing margins to recover, or if they signal deeper structural problems that will continue to weigh on earnings.
Bullish
- Dominant Market Position: Medline is the largest provider of medical-surgical products in the US, with over 190,000 branded products and 150,000 third-party items. This scale provides competitive advantages in procurement, logistics, and customer relationships, as evidenced by its prime vendor relationships with major health systems.
- Strong Revenue Growth: Revenue grew 10.7% YoY in Q1 2026 to $7.352 billion, continuing a trend of double-digit growth. The company's top line is supported by its dominant market position and essential nature of medical supplies, which provides demand stability.
- Significant Analyst Upside: The average analyst target price is $50.92, implying 29.1% upside from the current price of $39.44. The consensus recommendation is Buy with a mean score of 1.54 (1=Strong Buy), indicating strong bullish sentiment from 26 analysts.
- Healthy Free Cash Flow: Trailing twelve-month free cash flow is $1.525 billion, providing a cushion for capital needs and debt service. This cash generation supports the company's ability to invest in recovery from operational setbacks and maintain its dividend.
Bearish
- Declining Profitability: Net income fell 60% YoY in Q1 2026 to $129 million from $322 million, while gross margin contracted to 22.6% from 24.8% and operating margin dropped to 5.7% from 8.9%. This margin compression signals operational challenges and cost pressures.
- Operational Headwinds from Fire and FDA: A major distribution center fire and an FDA warning letter regarding homecare beds create significant near-term operational and financial challenges. These events could disrupt supply chains, increase costs, and damage customer trust.
- Decelerating Revenue Growth: Revenue growth decelerated from 12.0% in Q3 2025 to 11.5% in Q4 2025 and 10.7% in Q1 2026. This trend, combined with operational disruptions, suggests potential further slowdown, which could pressure the stock's valuation.
- High Debt-to-Equity Ratio: The debt-to-equity ratio of 1.17 indicates moderate leverage, which could strain finances if earnings continue to decline. Interest expense of $165 million in Q1 2026 consumes a significant portion of operating income.
MDLN Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of -10.6% and currently trading at 77.5% of its 52-week range (from low of $32.82 to high of $50.88). This positioning near the lower end of the range suggests a value opportunity but also reflects ongoing selling pressure and investor caution. The 3-month price change of -16.0% confirms the bearish trend, while the 1-month change of +5.7% shows a short-term bounce, indicating potential mean reversion or a temporary relief rally. The divergence between the 1-month and 3-month trends suggests the stock may be attempting to form a bottom, but the longer-term downtrend remains intact. The 52-week low of $32.82 serves as key support, while the 52-week high of $50.88 is resistance. A breakout above $50.88 would signal a trend reversal, while a breakdown below $32.82 could accelerate losses. Beta is not provided, but the stock's volatility is evident from its 33.6% maximum drawdown, implying higher risk than the broader market.
Beta
—
—
Max Drawdown
-33.6%
Largest decline past year
52-Week Range
$33-$51
Price range past year
Annual Return
—
Cumulative gain past year
| Period | MDLN Return | S&P 500 |
|---|---|---|
| 1m | +10.8% | +0.1% |
| 3m | -13.7% | +5.7% |
| 6m | -6.8% | +8.5% |
| 1y | — | +20.3% |
| ytd | +1.2% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDLN Fundamental Analysis
Revenue grew 10.7% year-over-year in Q1 2026 to $7.352 billion, but this decelerated from the 11.5% growth in Q4 2025 and 12.0% in Q3 2025, indicating a slowing trajectory. The company's top line is driven by its dominant position in medical-surgical supplies, but the recent distribution center fire and FDA issues may pressure near-term growth. Net income in Q1 2026 was $129 million, down significantly from $322 million in Q1 2025, reflecting margin compression. Gross margin fell to 22.6% from 24.8% a year ago, while operating margin dropped to 5.7% from 8.9%, highlighting cost pressures and operational challenges. The company remains profitable but with declining profitability. The balance sheet shows a debt-to-equity ratio of 1.17, indicating moderate leverage, and a current ratio of 4.29, suggesting strong liquidity. Free cash flow was $316 million in Q1 2026, down from $535 million in Q1 2025, but the company generated $1.525 billion in trailing twelve-month free cash flow, providing a cushion for capital needs. ROE of 10.8% is reasonable but has declined from prior quarters.
Quarterly Revenue
$7.4B
2026-03
Revenue YoY Growth
+10.7%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDLN Overvalued?
Since net income is positive, the PE ratio is the primary metric. The trailing PE is 29.4x, while the forward PE is 23.7x, implying the market expects earnings growth. The gap between trailing and forward PE suggests an anticipated improvement in earnings, which is consistent with analyst estimates of $2.37 EPS for the current year. Compared to the industry average (not provided), the stock's PE of 29.4x appears elevated relative to the broader market, but its forward PE of 23.7x is more reasonable. The PS ratio of 1.20x is low for a healthcare supplies company, reflecting the market's skepticism about near-term earnings power. Historically, the trailing PE has ranged from 24.4x to 69.5x over the past year, and the current 29.4x is near the lower end of that range, suggesting the stock is relatively cheap compared to its own history. However, the recent decline in profitability warrants caution.
PE
29.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 24x~48x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the sharp decline in profitability, with net income dropping 60% YoY and gross margin falling 220 basis points to 22.6%. The debt-to-equity ratio of 1.17 and interest expense of $165 million per quarter create leverage risk if earnings continue to deteriorate. Free cash flow, while still positive at $316 million in Q1 2026, declined 41% from $535 million a year ago, reducing the cushion for capital investments and debt service. The company's reliance on a single distribution center (now damaged by fire) poses a concentration risk to its supply chain and revenue generation.
Market & Competitive Risks: The stock's valuation at 29.4x trailing PE is above the broader market average, leaving it vulnerable to multiple compression if earnings disappoint. The decelerating revenue growth trend (from 12.0% to 10.7%) could lead to analyst downgrades and target price reductions. The FDA warning letter introduces regulatory risk that could result in product recalls or reputational damage, potentially affecting customer relationships. The stock's beta is not provided, but its 33.6% maximum drawdown suggests high sensitivity to market downturns and sector rotation away from growth stocks.
Worst-Case Scenario: If the distribution center fire and FDA issues lead to prolonged operational disruptions, customer losses, and further margin compression, earnings could fall below expectations. In this scenario, the stock could decline to its 52-week low of $32.82, representing a 16.8% downside from the current price of $39.44. If a recession or healthcare spending cuts compound these issues, the stock could test lower levels, potentially resulting in a loss of up to 35% from current levels, consistent with the historical max drawdown of 33.6%.
FAQ
The key risks are: 1) Operational risk from the distribution center fire and FDA warning letter, which could disrupt supply chains and increase costs. 2) Financial risk from declining profitability—net income fell 60% YoY and gross margin dropped to 22.6%. 3) Valuation risk—the trailing PE of 29.4x could compress further if earnings disappoint. 4) Macro risk—the stock's 33.6% max drawdown indicates high sensitivity to market downturns. The most severe risk is a prolonged operational disruption that leads to customer losses and further margin compression, potentially driving the stock to its 52-week low of $32.82.
The 12-month forecast is based on three scenarios: Bull case (25% probability) targets $50-$62, assuming rapid resolution of operational issues and margin recovery. Base case (50% probability) targets $40-$50, with gradual improvement and the stock reaching the average analyst target of $50.92. Bear case (25% probability) targets $32-$40, with prolonged disruptions and further margin decline. The base case is most likely, driven by the assumption that Medline's scale and essential products will allow it to overcome near-term headwinds. The AI assessment is bullish with medium confidence, citing strong revenue growth and attractive valuation.
MDLN appears undervalued relative to its own history and analyst targets. The trailing PE of 29.4x is near the low end of its 52-week range of 24.4x to 69.5x, suggesting the stock is cheap compared to its past. The forward PE of 23.7x implies the market expects earnings growth, which is consistent with analyst estimates of $2.37 EPS. The PS ratio of 1.20x is low for a healthcare supplies company, reflecting market skepticism about near-term earnings power. Compared to the broader market, the PE is elevated, but given the company's dominant position and growth, the valuation is reasonable. The average analyst target implies 29.1% upside, indicating the stock is undervalued.
MDLN appears to be a good buy for investors with a medium-to-long-term horizon who can tolerate near-term volatility. The stock offers a 29.1% upside to the average analyst target of $50.92, and the consensus recommendation is Buy. The forward PE of 23.7x is reasonable given expected EPS growth, and the company generates strong free cash flow of $1.525 billion TTM. However, the biggest downside risk is the operational disruption from the distribution center fire and FDA warning letter, which could further compress margins. For risk-tolerant investors, the current price near the low end of its historical valuation range presents an attractive entry point.
MDLN is more suitable for long-term investment due to its dominant market position, essential product portfolio, and potential for earnings recovery. The stock's 33.6% max drawdown and 16% three-month decline indicate high short-term volatility, making it risky for short-term traders. The dividend yield of 1.5% provides some income for long-term holders. Given the near-term operational headwinds, a minimum holding period of 12-18 months is recommended to allow time for the company to resolve issues and for earnings to recover. Long-term investors could benefit from the 29.1% upside to the average analyst target and potential multiple expansion.